直接抗病毒药物对慢性丙型肝炎特殊人群的治疗进展  

Treatment progress of chronic hepatitis C with direct-acting antivirals in special populations

作　　者：李元元[1] 史继静[1] 黄磊[1] 王福生[1] 

机构地区：[1]解放军第三0二医院感染性疾病诊疗与研究中心,北京100039

出　　处：《传染病信息》2017年第2期70-74,共5页Infectious Disease Information

基　　金：国家自然科学基金(81601731)

摘　　要：目前最新的口服直接抗病毒药物不再依赖于干扰素和利巴韦林,该类药对HCV治疗的有效率高达90%以上,这使得丙型肝炎(丙肝)成为可治愈的疾病。然而,在真实世界中,HCV感染的特殊人群(包括合并HIV、HBV共感染,肝移植、肝硬化、肾功能不全以及孕妇、儿童、老人等)的治疗有效率是偏低的,这对口服直接抗病毒药物提出挑战,解决这些挑战最好的办法是了解并掌握药物之间可能存在的风险,从而使更多丙肝特殊人群受益。With the latest all-oral interferon and ribavirin-free regimens based on direct acting antivirals against the HCV, sustained virological response rates of〉90% are achieved, which is equivalent to cure. However, outcomes in special patients with HCV infection tend to be lower and treatment of special patients is often challenging, such as HIV-positive persons, transplant recipients, patients with advanced cirrhosis, renal insufficiency, HBV coinfection, pregnancy, children and older patients. The best way to solve these challenges relies on understanding the potential risks of drug interactions, so as to be of benefits to more special populations with hepatitis C.

关 键 词：丙型肝炎病毒 慢性丙型肝炎 直接抗病毒药物 特殊人群 

分 类 号：R512.63[医药卫生—内科学]